Contrasting of Heat Biologics Inc. (HTBX) and NantKwest Inc. (NASDAQ:NK)

Heat Biologics Inc. (NASDAQ:HTBX) and NantKwest Inc. (NASDAQ:NK) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Heat Biologics Inc. N/A 0.00 32.57M -0.19 0.00
NantKwest Inc. 1 1.22 33.98M -1.09 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Heat Biologics Inc. and NantKwest Inc.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Heat Biologics Inc. 7,098,953,792.50% 0% 0%
NantKwest Inc. 2,860,510,143.95% -52.7% -43.1%

Volatility and Risk

Heat Biologics Inc.’s current beta is 1.83 and it happens to be 83.00% more volatile than S&P 500. Competitively, NantKwest Inc.’s beta is 2.34 which is 134.00% more volatile than S&P 500.

Liquidity

Heat Biologics Inc.’s Current Ratio is 5.7 while its Quick Ratio is 5.7. On the competitive side is, NantKwest Inc. which has a 4.1 Current Ratio and a 4.1 Quick Ratio. Heat Biologics Inc. is better positioned to pay off short and long-term obligations compared to NantKwest Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Heat Biologics Inc. and NantKwest Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Heat Biologics Inc. 0 0 1 3.00
NantKwest Inc. 0 0 0 0.00

The upside potential is 1,605.39% for Heat Biologics Inc. with consensus price target of $8.

Institutional & Insider Ownership

Heat Biologics Inc. and NantKwest Inc. has shares owned by institutional investors as follows: 10.9% and 8.5%. Insiders owned roughly 3.62% of Heat Biologics Inc.’s shares. Competitively, NantKwest Inc. has 21.5% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Heat Biologics Inc. 23.53% 1.47% -33% -49.95% -65.01% -27.53%
NantKwest Inc. 14.05% 33.98% 20% 25.45% -60.12% 18.97%

For the past year Heat Biologics Inc. had bearish trend while NantKwest Inc. had bullish trend.

Summary

Heat Biologics Inc. beats NantKwest Inc. on 7 of the 11 factors.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.